Differential expression of G1 cyclins and cyclin-dependent kinase inhibitors in normal and transformed melanocytes

Investigative Ophthalmology and Visual Science

Volumn 39, Issue 6, 1998, Pages 876-884

  Mouriaux, Frédéric ^a   Casagrande, Fabrice ^a   Pillaire, Marie Jeanne ^a   Manenti, Stéphane ^a   Malecaze, François ^a,b   Darbon, Jean Marie ^a  

^a INSERM   (France)

^b CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; CYCLINE; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL TRANSFORMATION; CHOROID MELANOMA; CONTROLLED STUDY; FIBROBLAST; HUMAN; HUMAN CELL; MELANOCYTE; MELANOMA CELL; PIGMENT CELL; PRIORITY JOURNAL;

CELL DIVISION; CELL LINE, TRANSFORMED; CHOROID NEOPLASMS; CYCLIN-DEPENDENT KINASES; CYCLINS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FIBROBLASTS; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; G1 PHASE; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; MELANOCYTES; MELANOMA; PIGMENT EPITHELIUM OF EYE; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 0031968802     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Scotto J, Fraumeni JF, Lee JA. Melanoma of the eye and other noncutaneous sites: epidemiologic aspects. J Natl Cancer Inst. 1976;56:489-491.
2. Halaban R. Growth regulation in normal and malignant melanocytes. In: Ferrone S, ed. Human Melanoma. Berlin: Springer-Verlag; 1988:3-14.
3. Hu DN, Mc Cormick SA, Ritch R, Pelton-Henrion K. Isolation, purification and cultivation of human uveal melanocytes. Invest Ophthalmol Vis Sci. 1993;34:2210-2219.
4. Hunter T, Pines J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell. 1994;79:573-582.
5. Motokura T, Arnold A. Cyclin D and oncogenesis. Curr Opin Gen Dev. 1993;3:5-10.
6. Buckley MF, Sweeny KJ, Hamilton JA, et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene. 1993; 8:2127-2133.
7. Keyomarsi K, Pardee AB. Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci USA. 1993;90:1112-1116.
8. Khatib ZA, Matsushime H, Valentine M, et al. Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res. 1993;53:5535-5541.
9. Ohtsubo M, Roberts JM. Cyclin-dependent regulation of G1 in mammalian fibroblasts. Science. 1993;259:1908-1912.
10. Resnitzky D, Gossen M, Bujard H, Reed SI. Acceleration of the G1/S phase transition by expression of cyclin D1 and E with inducible system. Mol Cell Biol. 1994;14:1669-1673.
11. Tam SW, Theodoras AM, Shay JW, Draetta GF, Pagano M. Differential expression and regulation of cyclin D1 protein in normal and tumor human cells:association with Cdk4 is required for cyclin D1 function in G1 progression. Oncogene. 1994;9:2663-2674.
12. Sherr Q, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995;9:1149-1163.
13. Yang ZY, Perkins ND, Ohno T, Nabel EG, Nabel GJ. The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nat Med. 1995;10:1052-1056.
14. Shiohara M, El-Deiry WS, Wada M, et al. Absence of WAF1 mutations in a variety of human malignancies. Blood. 1994;84:3781-3784.
15. Loda M, Cukor B, Tam SW, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med. 1997;3:231-234.
16. Porter PL, Malone KE, Heagerthy PJ, et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med. 1997;3:222-225.
17. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994;264:436-440.
18. Nobori T, Miura K, Wu DJ, et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 1994; 368:753-756.
19. Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nat Genet. 1994;8:15-21.
20. Nigg EA. Cyclin-dependent protein kinases: key regulators of the eukaryotic cell cycle. Bioessays. 1995;17:471-480.
21. MO15 catalytic subunit of cdk-activating kinase. Oncogene. 1994;9:3127-3138.
22. Fesquet D, Labbé JC, Derancourt J, et al. The MO15 gene encodes the catalytic subunit of a protein kinase that activates cdc2 and other cyclin-dependent kinases (CDKs) through phosphorylation of Thr161 and its homologues. EMBO J. 1993;12:3111-3121.
23. Fisher RP, Morgan DO. A novel cyclin associates with MO15/CDK7 to form the cdk-activating kinase. Cell. 1994;78:713-724.
24. MO15 associates with a p36 subunit and requires both nuclear translocation and Thr176 phosphorylation to generate cdk-activating kinase activity in Xenopus oocytes. EMBO J. 1994;13:5155-5164.
25. MO15. EMBO J. 1993;12:3133-3142.
26. Tassan JP, Schultz SJ, Bartek J, Nigg EA. Cell cycle analysis of the activity, subcellular localization, and subunit composition of human CAK (CDK-activating kinase). J Biol Chem. 1994;127:467-478.
27. Devault A, Martinez AM, Fesquet D, et al. MAT1 ("menage a trois") a new RING finger protein subunit stabilizing cyclin H-cdk7 complexes in starfish and Xenopus CAK. EMBO J 1995;14:5027-5036.
28. Fisher RP, Jin P, Chamberlin HM, Morgan DO. Alternative mechanisms of CAK assembly require an assembly factor or an activating kinase. Cell. 1995;83:47-57.
29. Tassan JP, Jaquenoud M, Fry AM, et al. In vitro assembly of a functional human CDK7-cyclin H complex requires MAT1, a novel 36 kDa RING finger protein. EMBO J 1995;14:5608-5617.
30. Bartkova J, Zemanova M, Bartek J. Expression of CDK7/CAK in normal and tumour cells of diverse histogenesis, cell-cycle position and differentiation. Int J Cancer. 1996;66:732-737.
31. Krasagakis K, Garbe C, Schrier PI, Orfano CE. Paracrine and autocrine regulation of human melanocyte and melanoma cell growth by transforming growth factor beta in vitro. Anticancer Res. 1994; 14:2565-2572.
32. Pietenpol JA, Stein RW, Moran E, et al. TGF-β1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRb binding domains. Cell. 1990;61: 777-785.
33. Burnier MN, McLean IW, Gamel JW. Immunohistochemical evaluation of uveal melanocyte tumors. Cancer. 1991;68:809-814.
34. Bates S, Parry D, Bonetta L, et al. Absence of cyclin D/cdk complexes in cells lacking functional retinoblastoma protein. Oncogene. 1994;9:1633-1640.
35. Lukas J, Müller H, JB, et al. DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1. J. Cell Biol. 1994;125: 625-638.
36. Quelle DE, Ashmun RA, Shurtleff SA, et al. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Gene Dev. 1993;7:1559-1571.
37. Müller H, Lukas J, Schneider A, et al. Cyclin D1 expression is regulated by the retinoblastoma protein. Proc Natl Acad Sci USA. 1994;91:2945-2949.
38. Ludlow JW, DeCaprio JA, Huang CM, et al. SV40 large T antigen binds preferentially to an underphosphorylated member of the retinoblastoma susceptibility gene product family. Cell. 1989;56-57-65.
39. Kip1 by the viral E1A oncoprotein in TGFβ-treated cells. Nature. 1996;380: 262-265.
40. Ewen ME, Sluss HK, Whitehouse LL, Livingston DM. TGF-β inhibition of Cdk4 synthesis is linked to cell cycle arrest. Cell. 1993;74: 1009-1020.
41. Wang YL, Uhara H, Yamasaki Y, Nikaido T, Saida T. Immunohistochemical detection of CDK4 and p16(INK4) proteins in cutaneous malignant melanoma. Br J Dermat. 1996;134:269-275.
42. Matsuoka M, Kato J-Y, Fisher RP, Morgan DO, Sherr CJ Activation of cyclin-dependent kinase 4 (cdk4) by mouse MO15-associated kinase. Mol Cell Biol. 1994;14:7265-7275.
43. MO15. J Cell Sci. 1994; 107:2789-2799.
44. Roy R, Adamczewski JP, Seroz T, et al. The MO15 cell cycle kinase is associated with the TFIIH transcription-DNA repair factor. Cell. 1994;79:1093-1101.
45. Serizawa H, Mäkelä TP, Conaway JW, et al. Association of Cdk-activating kinase subunits with transcription factor TFIIH. Nature. 1995;374:280-282.
46. Shiekhattar R, Mermelstein F, Fisher RP, et al. Cdk-activating kinase complex is a component of human transcription factor TFIIH. Nature. 1995;374:283-287.
47. Kawamata N, Morosetti R, Miller CW, et al. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res. 1995;55:2266-2269.
48. kip1 gene to 12p13 and its analysis in leukemias. Cancer Res. 1995;55:1206-1210.
49. Kip1, a cyclin-cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev. 1994;8:9-22.
50. Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell. 1996;85:707-720.
51. cip1 arrests the growth of chicken embryo fibroblasts transformed by individual oncogenes. Oncogene. 1995;11:2609-2618.
52. CIP1/WAF1 underg0 normal development, but are defective in G1 checkpoint control. Cell. 1995;82:675-684.
53. Jiang H, Lin J, Su ZZ, et al. The melanoma differentiation-associated gene mda-6, which encodes the cyclin-dependent kinase inhibitor p21, is differentially expressed during growth, differentiation and progression in human melanoma cells. Oncogene. 1995;10:1855-1864.
54. Vidal MJ, Loganzo F, De Oliveira AR, Hayward NK, Albino AP. Mutations and defective expression of the WAF1 p21 tumor-suppressor gene in malignant melanomas. Melanoma Res. 1995;5: 243-250.
55. WAF1/Cip1 in human brain tumors. Oncogene. 1995;11:2021-2028.
56. Trotter MJ, Tang L, Tron VA. Overexpression of the cyclin-dependent kinase inhibitor p21 (WAF1/CIP1) in human cutaneous malignant melanoma. J Cutan Pathol. 1997;24:265-271.
57. Serrano M, Lee HW, Chin L, et al. Role of the INK4a locus in tumor suppression and cell mortality. Cell. 1996;85:27-37.
58. Talve L, Sauroja I, Collan Y, Punnonen K, Ekfors T. Loss of expression of the p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage. Int J Cancer. 1997;74:255-259.
59. Reymond A, Brent R. p 16 proteins from melanoma-prone families are deficient in binding to Cdk4. Oncogene. 1995;11:1173-1178.